-
Ro 3306 for CDK1-Mediated G2/M Control
2026-09-02
Ro 3306 is a selective CDK1 inhibitor for synchronizing proliferating cells, dissecting mitotic entry, and testing DNA repair dependencies. Its value extends beyond simple G2/M arrest: paired with phase-aware mTORC1 measurements, it can separate cell-cycle effects from metabolic and autophagy responses.
-
Tetrazolium (chloride) for Viability Workflows
2026-09-02
Tetrazolium (chloride), also called Tetrazolium Red, converts dehydrogenase activity into a measurable red formazan signal for cell and tissue studies. This guide emphasizes practical workflows for mitochondrial function assays, ischemic lesion mapping, controls, and troubleshooting rather than treating color intensity as a standalone mechanism.
-
Dual HER2–VEGFR2 Targeting in TNBC Metastasis
2026-09-01
The reference study evaluates lapatinib plus Telatinib (BAY 57-9352) in HER2-negative MDA-MB-231 triple-negative breast cancer cells, focusing on proliferation, invadopodia formation, and angiogenic tube formation. Its main contribution is a phenotype-centered preclinical framework for testing coordinated HER2/VEGFR2 pathway inhibition, while the in vitro design does not establish molecular target engagement, pharmacological synergy, or clinical efficacy.
-
Nonselective β-Blockade Delays HCT Engraftment
2026-09-01
Nishino and colleagues show that nonselective β-adrenergic blockade, exemplified by carvedilol, can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective blockade has substantially less effect. By combining mouse transplantation experiments with human cohort analyses, the study identifies β-receptor selectivity, transplant setting, posttransplant chemotherapy, and graft cell dose as clinically relevant determinants of engraftment.
-
Hyperthermia–Cisplatin Activates Caspase-8
2026-08-31
A 2024 study shows that hyperthermia strengthens cisplatin-induced cancer-cell death by promoting Cullin 3-associated K63-linked polyubiquitination, accumulation, and activation of caspase-8. The resulting pathway links caspase-3-mediated apoptosis with gasdermin-associated pyroptosis and provides a mechanistic framework for interpreting combination-therapy responses.
-
Grazoprevir/Elbasvir Therapy for HCV: Evidence Review
2026-08-31
The reference review explains why combining the NS3/4A protease inhibitor grazoprevir with the NS5A inhibitor elbasvir created a compact, interferon-free strategy for HCV treatment. Its synthesis emphasizes high sustained virologic response rates, activity in difficult-to-treat populations, resistance-aware treatment selection, and the importance of interpreting trial and real-world evidence separately.
-
Bufuralol hydrochloride in Organoid PK Workflows
2026-08-30
Bufuralol hydrochloride combines broad β-adrenoceptor blockade with partial intrinsic sympathomimetic activity, making it useful for separating receptor effects from exposure and metabolism. When paired with human iPSC-derived intestinal organoids, it supports a more human-relevant workflow for cardiovascular pharmacology research and translational pharmacokinetic studies.
-
TAI-1 Hec1 Inhibitor: Assays and Workflows
2026-08-29
TAI-1 enables mechanism-led studies of Hec1 disruption, chromosome misalignment, and apoptotic cell death across cancer models. This guide translates its reported potency and combination activity into practical dose-response, microscopy, genotype, and troubleshooting workflows while separating direct evidence from exploratory assay design.
-
KPT-330 (Selinexor): From Nuclear Export to Translation
2026-08-28
A translational framework for using KPT-330 (Selinexor) to connect CRM1 biology with biomarker strategy, combination design, and reproducible oncology workflows.
-
MK-0812 Workflow for MASH Inflammation
2026-08-28
Use MK-0812 as a mechanistic probe for CCR2-dependent monocyte trafficking in gut–liver inflammation research. Its whole-blood potency, mouse pharmacology, and DMSO solubility support workflows that connect immune-cell recruitment with intestinal TM6SF2, microbiota, and MASH phenotypes.
-
S Tag Peptide (A6007): Practical Workflow Guide
2026-08-27
S Tag Peptide (SKU A6007) is a soluble 15-amino-acid tag for recombinant protein detection, antibody-based purification, and protein solubility improvement. It is best used in aqueous workflows or genetically encoded fusions and should not be treated as a standalone RNase reagent or stored as an ethanol-based solution.
-
Tadalafil-Primed MSC Exosomes in Pulmonary Hypertension
2026-08-27
The reference study shows that tadalafil pretreatment changes the therapeutic activity of mesenchymal stem cell-derived exosomes in pulmonary hypertension. Its central mechanistic contribution is a CREB1–miR-29a-3p–ENPP2 axis that connects exosome-mediated anti-inflammatory effects with reduced vascular remodeling, while also identifying experimental opportunities for more precise proliferation analysis.
-
Brassinolide Workflows for Plant and Translational Research
2026-08-26
Brassinolide supports a distinctive cross-domain workflow: benchmark plant growth activity with rice lamina inclination assays, then investigate apoptosis and metabolic endpoints with formulation-aware mammalian experiments. This guide connects practical handling, assay controls, structure–activity insights, and troubleshooting for more reproducible cancer research and diabetes research.
-
MOG (35-55) for EAE Research Workflows
2026-08-26
MOG (35-55) is a practical myelin oligodendrocyte glycoprotein peptide for building reproducible autoimmune encephalomyelitis models and connecting neurological phenotypes with immune and molecular readouts. This guide emphasizes preparation, dose selection, assay design, PARP7–STAT1/2 interpretation, and troubleshooting rather than peptide description alone.
-
Z-WEHD-FMK: A Translational View of Pyroptosis
2026-08-25
Caspase-1 is more than a terminal pyroptosis effector: it can function as a transcriptionally controlled switch linking tumor cell fate, inflammation, and pathogen biology. This article explains how Z-WEHD-FMK, also known as Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK, can help translational researchers distinguish caspase dependence from upstream pathway architecture while designing more rigorous inflammation, cancer, and infectious disease studies.